Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart

被引:264
作者
Rocha, R
Martin-Berger, CL
Yang, PC
Scherrer, R
Delyani, J
McMahon, E
机构
[1] Pharm Corp, Cardiovasc & Metab Dis, Skokie, IL 60077 USA
[2] Pharm Corp, Cardiovasc & Metab Dis, St Louis, MO 63167 USA
关键词
D O I
10.1210/en.2002-220120
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We studied the role of aldosterone (aldo) in myocardial injury in a model of angiotensin (Ang) II-hypertension. Wistar rats were given 1% NaCl (salt) to drink and randomized into one of the following groups (n = 10; treatment, 21 d): 1) vehicle control (VEH); 2) Ang II infusion (25 ng/min, sc); 3) Ang II infusion plus the selective aldo blocker, eplerenone (epl, 100 mg/kg.d, orally); 4) Ang II infusion in adrenalectomized (ADX) rats; and 5) Ang II infusion in ADX rats with aldo treatment (20 mug/kg.d, sc). ADX rats received also dexamethasone (12 mug/kg.d, sc). Systolic blood pressure increased with time in all treatment groups except the VEH group (VEH,136 +/- 6; Ang II/NaCl, 203 +/- 12; Ang II/NaCl/epl, 196 +/- 10; Ang II/NaCl/ADX, 181 +/- 7; Ang II/NaCl/ADX/aldo, 236 +/- 8 mm Hg). Despite similar levels of hypertension, epl and ADX attenuated the increase in heart weight/body weight induced by Ang II. Histological examination of the hearts evidenced myocardial and vascular injury in the Ang II/salt (7 of 10 hearts with damage, P < 0.05 vs. VEH) and Ang II/salt/ADX/aldo groups (10 of 10 hearts with damage, P < 0.05). Injury included arterial fibrinoid necrosis, perivascular inflammation (primarily macrophages), and focal infarctions. Vascular lesions were associated with expression of the inflammatory mediators cyclooxygenase 2 (COX-2) and osteopontin in the media of coronary arteries. Myocardial injury, COX-2, and osteopontin expression were markedly attenuated by epl treatment (1 of 10 hearts with damage, P < 0.05 vs. Ang II/salt) and adrenalectomy (2 of 10 hearts with damage, P < 0.05 vs. Ang II/salt). Our data indicate that aldo plays a major role in Ang II-induced vascular inflammation in the heart and implicate COX-2 and osteopontin as potential mediators of the damage.
引用
收藏
页码:4828 / 4836
页数:9
相关论文
共 23 条
[1]   Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity [J].
Ashkar, S ;
Weber, GF ;
Panoutsakopoulou, V ;
Sanchirico, ME ;
Jansson, M ;
Zawaideh, S ;
Rittling, SR ;
Denhardt, DT ;
Glimcher, MJ ;
Cantor, H .
SCIENCE, 2000, 287 (5454) :860-864
[2]  
Belton O, 2000, CIRCULATION, V102, P840
[3]   Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease [J].
Cowan, KN ;
Jones, PL ;
Rabinovitch, M .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) :21-34
[4]   Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival [J].
Denhardt, DT ;
Noda, M ;
O'Regan, AW ;
Pavlin, D ;
Berman, JS .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (09) :1055-1061
[5]   Mineralocorticoid receptor affects AP-1 and nuclear factor-κB activation in angiotensin II-Induced cardiac injury [J].
Fiebeler, A ;
Schmidt, F ;
Müller, DN ;
Park, JK ;
Dechend, R ;
Bieringer, M ;
Shagdarsuren, E ;
Breu, V ;
Haller, H ;
Luft, FC .
HYPERTENSION, 2001, 37 (02) :787-793
[6]   Experimental cardiac fibrosis: Differential time course of responses to mineralocorticoid-salt administration [J].
Fujisawa, G ;
Dilley, R ;
Fullerton, MJ ;
Funder, JW .
ENDOCRINOLOGY, 2001, 142 (08) :3625-3631
[7]   OSTEOPONTIN OVEREXPRESSION IS ASSOCIATED WITH ARTERIAL SMOOTH-MUSCLE CELL-PROLIFERATION INVITRO [J].
GADEAU, AP ;
CAMPAN, M ;
MILLET, D ;
CANDRESSE, T ;
DESGRANGES, C .
ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (01) :120-125
[8]  
GAVRAS H, 1971, LANCET, V2, P19
[9]  
GIACOMELLI F, 1976, AM J PATHOL, V84, P111
[10]   Angiotensin II directly increases transforming growth factor β1 and osteopontin and indirectly affects collagen mRNA expression in the human heart [J].
Kupfahl, C ;
Pink, D ;
Friedrich, K ;
Zurbrügg, HR ;
Neuss, M ;
Warnecke, C ;
Fielitz, J ;
Graf, K ;
Fleck, E ;
Regitz-Zagrosek, V .
CARDIOVASCULAR RESEARCH, 2000, 46 (03) :463-475